Zhuhai Gree Group's Long Position In Kintor Pharmaceutical Falls To 6.77% - HKEX Filing
14 days ago
Kintor Pharmaceutical Expects To Commence Phase III Clinical Trial Of Kx-826 In China In Q4
21 days ago
Kintor Gets NMPA Approval For Trials Of Proxalutamide To Treat COVID-19 In China
About Kintor Pharmaceutical Ltd
Kintor Pharmaceutical Ltd is a clinical-stage novel drug developer in China. The Company is focused on the research and development of drugs for cancers and other androgen receptor (AR) related diseases. Its primary drug candidate is Proxalutamide which is in phase III clinical trials in China for metastatic castration-resistant prostate cancer (mCRPC). The Company are also developing other drug candidates, including a phase II small molecule drug candidate Pyrilutamide, a phase II monoclonal antibody drug candidate ALK-1, a phase I mTOR inhibitor drug candidate Detorsertib and an inhibitor of the hedgehog signal translation pathway GT1708F.